A wave of studies at the year's biggest cancer conference suggests the GLP 1 drug class — which includes Ozempic and Wegovy — protect against several cancers, and a lung cancer result hints the benefit is more than just pounds shed.
The lung cancer finding is the data point that does not fit the script. Across more than forty studies presented last month at the American Society of Clinical Oncology (ASCO) annual meeting, GLP-1 drugs such as Ozempic and Wegovy showed signals of protecting patients against cancer. Most of those cancers have a known link to obesity, so weight loss alone could plausibly explain the effect. Lung cancer is not one of them, and that absence is the most interesting thing in the data.
The broader pattern is striking even before the lung cancer exception. In one study that followed roughly 110,000 women aged 45 to 80, GLP-1 users were about 30 percent less likely to develop breast cancer, according to an abstract presented at ASCO. Separate work tracked lower recurrence rates in patients who stayed on the drugs. Six of seven cancer types examined showed a protective signal in the conference's most-discussed presentation, with the strongest results in colorectal, breast, liver, and lung cancer. That kind of convergence across many independent cohorts is what researchers mean when they call a signal "real, but early."
Gilberto de Lima Lopes, chief of medical oncology at the Sylvester Comprehensive Cancer Center at the University of Miami, told The Washington Post that "the potential benefit is real, and it makes biological sense." The qualifier matters. These are observational studies, which track outcomes in people who are already taking the drug. They can be skewed by who gets prescribed GLP-1s in the first place, how long they stay on them, and the health behaviors that come with regular contact with the medical system. They show correlation, not proof of cause. The 30 percent breast cancer figure, drawn from a single cohort of 110,000 women, is especially vulnerable to that kind of confounding, and randomized controlled data at scale does not yet exist for any cancer endpoint.
The most interesting question is what is doing the protecting. Obesity is a known risk factor for at least twelve types of cancer, so some share of the benefit is reasonably attributable to weight loss. But weight loss alone does not fully account for the magnitude of the observed effect, a co-author told NPR. The drugs may also work by dampening chronic inflammation, a known driver of tumor development, or by suppressing tumor growth directly, independent of their metabolic effects — early signals that researchers say are worth investigating further.
The lung cancer result is the cleanest evidence on the table that something biological is happening beyond pounds shed. Lung cancer has no established obesity link, so a reduction in that population is hard to attribute to weight loss. It is also preliminary, drawn from a subgroup in a presentation rather than a published randomized trial, and it is the kind of finding that often shrinks on replication. The honest framing is that it raises a question worth answering, not that it settles one.
If the mechanism question breaks toward a real anti-inflammatory or direct anti-tumor effect, the implications extend well beyond cancer prevention. It would expand the patient population worth studying far beyond the one currently eligible for weight-loss prescriptions, and it would put a cheap, generic-friendly drug class on the table as an adjuvant candidate for several tumor types. It would also reframe the GLP-1 conversation, which has so far been dominated by cardiovascular outcomes and weight, into a much broader pharmacology story.
The work that would actually settle the question is still ahead. Researchers need prospective randomized trials designed with cancer endpoints rather than weight loss as the primary outcome, and they need them in cancer-specific populations, not in diabetes or obesity cohorts with cancer as a secondary look. They also need biomarker work on tumor microenvironments to see whether GLP-1 exposure changes the local immune landscape around early tumors.
Until then, the honest read of the ASCO data is straightforward. GLP-1s appear to do something useful against cancer. The signal is broad enough across more than forty studies to take seriously, and the lung cancer result is the strongest single piece of evidence that the benefit is not just collateral damage from a smaller body. Whether the effect is real, how large it is, and whether it is driven by weight loss, by anti-inflammatory action, or by something more direct are the questions worth watching in the next round of trials.